Redwire Awarded $44 Million DARPA Contract to Advance Very Low-Earth Orbit Mission
JACKSONVILLE, Fla.–(BUSINESS WIRE)–$RDW–Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced... Read more.
Driven Brands to Participate in the Morgan Stanley Global Consumer & Retail Conference
CHARLOTTE, N.C.–(BUSINESS WIRE)–Driven Brands Holdings Inc. (NASDAQ: DRVN) (“Driven Brands” or the “Company”) today announced that it will participate... Read more.
Micro-ultrasound Proven Non-Inferior to MRI for Prostate Cancer Diagnosis in OPTIMUM Randomized Trial
Study data, published in JAMA and presented at EMUC 2025, suggest ExactVu is potential MRI alternative for image-guided prostate biopsy MARKHAM, Ontario–(BUSINESS... Read more.
Boston Cell Standards: Calibration Transforms Accuracy in HER2-Low Breast Cancer Testing
International Study Published in Lancet: eBioMedicine BOSTON–(BUSINESS WIRE)–#biotech—Boston Cell Standards today announced the publication of... Read more.
Scott Millard Named IonQ’s New Chief Business Officer
COLLEGE PARK, Md.–(BUSINESS WIRE)–IonQ (NYSE: IONQ), the world’s leading quantum company, today announced that Scott Millard will join the company... Read more.
Impact Communications Clients Shine as 2025 ThinkAdvisor Luminaries Award Finalists
Advyzon, Advyzon Investment Management, Syntax Data, The Oasis Group, Libretto, Kwanti, StraightLine, and EncorEstate Plans recognized for innovation and transformative... Read more.
Ryder & BJC Health System Secure SMI Collaboration Award for Transforming Healthcare Supply Chain, Enhancing Patient Care
Strategic Collaboration Delivers Near 100% Fulfillment Rates, 100% Real-Time Visibility, and Resilient Medical Logistics Across 14 Hospitals MIAMI–(BUSINESS... Read more.
Bullish Reports Third Quarter 2025 Results
Bullish posts record Adjusted Revenue, Adjusted EBITDA, and Adjusted Net Income for Q3’2025 Bullish beats guided ranges on Subscription, Services, & Other... Read more.
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
Investigational DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority to BIC/FTC/TAF in a Phase 3 clinical trial in treatment-naïve adults... Read more.
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. Announces Preliminary Results of Rights Offering
WEST PALM BEACH, Fla.–(BUSINESS WIRE)–RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (the “Fund”) (NYSE: OPP) today announced the preliminary... Read more.